Company Analysis Krystal Biotech, Inc.
1. Summary
Advantages
- The stock's return over the last year (2.54%) is higher than the sector average (-30.92%).
- Current debt level 0.6877% is below 100% and has decreased over 5 years from 1.56%.
- The company's current efficiency (ROE=10.34%) is higher than the sector average (ROE=9.69%)
Disadvantages
- Price (177.37 $) is higher than fair price (45.1 $)
- Dividends (0%) are below the sector average (0.5448%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Krystal Biotech, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -1.4% | -22.5% | -2.4% |
| 90 days | 8.4% | -31.9% | -12.5% |
| 1 year | 2.5% | -30.9% | 8.9% |
KRYS vs Sector: Krystal Biotech, Inc. has outperformed the "Healthcare" sector by 33.45% over the past year.
KRYS vs Market: Krystal Biotech, Inc. has significantly underperformed the market by -6.39% over the past year.
Stable price: KRYS is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: KRYS with weekly volatility of 0.0488% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (177.37 $) is higher than the fair price (45.1 $).
Price is higher than fair: The current price (177.37 $) is 74.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (53.3) is lower than that of the sector as a whole (57.21).
P/E vs Market: The company's P/E (53.3) is higher than that of the market as a whole (48.7).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (5.02) is higher than that of the sector as a whole (4.65).
P/BV vs Market: The company's P/BV (5.02) is higher than that of the market as a whole (3.42).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (16.36) is lower than that of the sector as a whole (33.44).
P/S vs Market: The company's P/S indicator (16.36) is higher than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (40.17) is higher than that of the sector as a whole (-17.68).
EV/Ebitda vs Market: The company's EV/Ebitda (40.17) is higher than that of the market as a whole (25.23).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -75.44% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-75.44%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (156.84%).
5.4. ROE
ROE vs Sector: The company's ROE (10.34%) is higher than that of the sector as a whole (9.69%).
ROE vs Market: The company's ROE (10.34%) is higher than that of the market as a whole (8.97%).
5.5. ROA
ROA vs Sector: The company's ROA (9.51%) is higher than that of the sector as a whole (0.2896%).
ROA vs Market: The company's ROA (9.51%) is higher than that of the market as a whole (6.31%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (10.96%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.5448%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Buying Exceeds insider sales by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 28.02.2025 | Krishnan Krish S President and CEO |
Purchase | 178.55 | 5 356 500 | 30 000 |
| 28.02.2025 | Krishnan Krish S President and CEO |
Purchase | 178.55 | 8 481 120 | 47 500 |
| 28.02.2025 | Krishnan Suma President, R&D |
Purchase | 178.55 | 8 481 120 | 47 500 |
| 11.06.2024 | Krishnan Krish S President and CEO |
Sale | 175.76 | 4 394 000 | 25 000 |
| 11.06.2024 | Krishnan Suma President, R&D |
Sale | 175.77 | 4 394 250 | 25 000 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
